AUSTIN, TEXAS, July 24, 2017 – LifeLine Software, Inc., a worldwide leader in dosimetric quality assurance tools, is pleased to announce that an agreement has been signed to acquire Radify, a Monte Carlo 3D dose volume QA software technology developed at McGill University in Quebec, Canada.

This acquisition and joint collaboration allows LifeLine Software to bring to market industry-changing 3D dose volume independent dosimetric verification products. LifeLine Software’s integration of the Radify technology will immediately improve accessibility to the significant advantage of Monte Carlo accuracy in clinical settings, specifically for verifying photon, electron, and proton treatment plans.

Monte Carlo is widely recognized as the gold standard dose calculation method. The most challenging clinical cases and complex structures are analyzed with the highest accuracy and confidence. Flexible implementation options and the uncompromised accuracy of a Monte Carlo dose calculation algorithm assist radiation departments to meet their workflow requirements.

"At LifeLine Software, we have always strived to meet and exceed our customers' expectations and to listen to their needs”, said LifeLine Software’s CEO and Co-Founder Craig Laughton. “With the increasing complexity of treatment delivery, the demand for sophisticated quality assurance tools has grown. This acquisition represents our hard work and commitment to our customers to bring the best 3D dose validation tools to the market. We believe the Monte Carlo dose calculation technology provided by the McGill Medical Physics Unit will not only meet our customers' needs but exceed their expectations."

The McGill-affiliated inventors of the Radify technology, Marc-Andre Renaud, François DeBlois and Jan Seuntjens, are experts in Monte Carlo techniques in various medical physics applications, from dosimetry and beam modeling, to treatment planning.

“We are excited to be working with an extraordinary group of medical physicists who have developed a world-class quality assurance software benefiting potentially millions of cancer patients worldwide. Our goal is to receive FDA clearance within the next 18 months” said LifeLine Software’s Co-Founder and President, Jim Dube.

Details of this new technology and our other new 3D Dose Volume QA software package, including RadCalc EPID, the first fully automated Pre-Treatment and 3D In-Vivo Exit dose verification software that provides a complete suite of 3D Dose Volume verification analysis tools and which includes Image Analysis and EPID based measurement functions, are available at our AAPM booth. Demonstrations can be booked directly at the LifeLine Software booth #5091.

Rad Oncology Homepage